Naviscan reported that a study published in the Journal of Nuclear Medicine showed positron emission mammography with breast cancer radiotracer Cu-64-TP3805 was effective in identifying 100% of malignant lesions in 13 patients. Researchers from Thomas Jefferson University utilized PEM imaging with Cu-64-TP3805 and F-18 FDG PET and were able to detect 20 malignant lesions. TP3805 is a compound licensed by NuView Life Sciences that binds to the molecules  expressed on all breast cancer cells early in malignancy.

Related Summaries